NASDAQ:CRSP

Crispr Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CRSP

*Your capital is at risk

$52.08

+0.0600 (+0.115%)

At Close: Jun 03, 2026

CRISPR Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -42.85. In total, the insiders bought 1.4M and sold 364.31K CRSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-42.85
● Buy	1.4M shares
● Sell	364.31K shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jan 22, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -42.85. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 90.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 16, 2026 Sell	Common Shares S-Sale	Patel Naimish Chief Medical Officer	Officer	3 150 Value: $152.0K
Mar 16, 2026 Sell	Common Shares S-Sale	Prasad Raju Chief Financial Officer	C-Suite Officer	5 848 Value: $282.2K
Mar 16, 2026 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	3 450 Value: $166.5K
Mar 16, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	10 349 Value: $499.4K
Mar 14, 2026 Buy	Common Shares M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	6 875 Value: $358.1K
Mar 14, 2026 Buy	Restricted Stock Units M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	10 000 Value: $520.8K
Mar 14, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	10 000 Value: $520.8K
Mar 14, 2026 Buy	Common Shares M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 875 Value: $358.1K
Mar 14, 2026 Buy	Common Shares M-Exempt	Patel Naimish Chief Medical Officer	Officer	8 125 Value: $423.2K
Mar 14, 2026 Buy	Restricted Stock Units M-Exempt	Patel Naimish Chief Medical Officer	Officer	8 125 Value: $423.2K
Mar 14, 2026 Buy	Restricted Stock Units M-Exempt	Prasad Raju Chief Financial Officer	C-Suite Officer	6 875 Value: $358.1K
Mar 14, 2026 Buy	Restricted Stock Units M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	6 875 Value: $358.1K
Mar 14, 2026 Buy	Common Shares M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	20 625 Value: $1.07M
Mar 14, 2026 Buy	Restricted Stock Units M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	20 625 Value: $1.07M
Mar 11, 2026 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	2 800 Value: $147.8K
Mar 11, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	9 798 Value: $517.3K
Mar 10, 2026 Buy	Common Shares M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	19 250 Value: $1.02M
Mar 10, 2026 Buy	Restricted Stock Units M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	5 500 Value: $290.4K
Mar 10, 2026 Buy	Common Shares M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	5 500 Value: $290.4K
Mar 10, 2026 Buy	Restricted Stock Units M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	19 250 Value: $1.02M
Feb 19, 2026 Sell	Common Shares S-Sale	Kasinger James R. General Counsel And Secretary	Officer	2 112 Value: $111.0K
Feb 19, 2026 Sell	Common Shares S-Sale	Kulkarni Samarth Chief Executive Officer	CEO / President	6 967 Value: $366.3K
Feb 18, 2026 Buy	Restricted Stock Units M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	3 825 Value: $204.7K
Feb 18, 2026 Buy	Common Shares M-Exempt	Kasinger James R. General Counsel And Secretary	Officer	3 825 Value: $204.7K
Feb 18, 2026 Buy	Restricted Stock Units M-Exempt	Kulkarni Samarth Chief Executive Officer	CEO / President	13 250 Value: $709.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CRISPR THERAPEUTICS AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglo...

Read Full Profile Here